Clarity Pharma shares jump on new diagnostic trial results
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Clarity Pharmaceuticals surged in early trading after the radiopharmaceutical company released results from its phase two 'DISCO' trial.
The topline data confirmed that Clarity's imaging agent Cu-SARTATE is "safe and highly effective" at detecting lesions in patients with neuroendocrine tumours (NET).
The numbers: Clarity shares were up 6.7% to $2.22 at 10:40am AEST.
The context: Following the preliminary results, Clarity said it will begin the next steps towards a phase 3 study of Cu-SARTATE in NETs with the US Food and Drug Administration's (FDA) guidance.
What they said: "We plan to rapidly progress discussions with the FDA to initiate a diagnostic registrational phase 3 study, as a first key step in expanding SARTATE into the theranostic field of NETS..." said Clarity's executive chairperson Alan Taylor.
"If the findings from the DISCO trial are substantiated in a registrational phase 3 study and lead to regulatory approval by the US FDA, Cu-SARTATE may play an important role in improving diagnostic accuracy, lesion detection and staging of patients with NETs."
The source: ASX
